New-onset refractory status epilepticus (NORSE) is a rare but critical neurologic condition characterized by the occurrence of a prolonged period of refractory seizures without a clear acute or active structural, toxic, or metabolic cause. 1 Identifying the underlying etiology is crucial for effectively managing and predicting the prognosis of NORSE. However, the cause of NORSE in approximately half of affected patients remains uncertain despite extensive investigations. 2 Herein we report the first case of encephalitis with anti-SOX1 antibodies presenting with NORSE that responded favorably to immunosuppressive therapy.
JCN fractory to appropriate doses of two or more types of antiepileptic drugs without a clear structural, toxic, or metabolic cause in patients without active epilepsy or a pre-existing relevant neurological disorder. 3 A nonparaneoplastic autoimmune or paraneoplastic etiology is the most common finding in NORSE. A large case series of 130 NORSE patients found that this condition was associated with various autoantibodies, especially anti-N-methyl-D-aspartate receptor (NMDA) and anti-voltage-gated potassium channel (VGKC)-complex antibodies. 2 However, some cases of cryptogenic NORSE showed a favorable response to immunosuppressive therapy, suggesting that there are unknown autoantibodies in NORSE. 4 To the best of our knowledge NORSE has not been reported previously in a patient with encephalitis with anti-SOX1 antibodies, and so the present findings are the first to suggest that anti-SOX1 antibodies can be considered an associated factor of NORSE. Antibodies against SOX1 have been reported to occur in paraneoplastic neuropathy and Lambert-Eaton myasthenic syndrome. 5, 6 In rare cases anti-SOX1 antibodies are related to paraneoplastic limbic encephalitis, 5 which is supported by the EEG findings of our patient. The most common type of cancer associated with anti-SOX1 antibodies is smallcell lung cancer, but other types of lung cancer have also been reported. 5, 6 The titers of anti-SOX1 antibodies and anti-NMDA and anti-VGKC-complex antibodies were not tested in our patient, which may be a limitation of this study. We therefore cannot exclude the possibility that anti-SOX1 antibodies are simply a bystander. However, given that the association between non-small-cell lung cancer and anti-NMDA and anti-VGKC-complex antibodies remains unclear, 7 bias from misdiagnosis due to the presence of these antibodies is not likely to be significant.
